Evrysdi Favored for Public Health Plans in Canada, Within Limits

Evrysdi Favored for Public Health Plans in Canada, Within Limits

305263

Evrysdi Favored for Public Health Plans in Canada, Within Limits

A branch of the Canadian Agency for Drugs and Technologies in Health (CADTH) is recommending that Evrysdi (risdiplam) be added to public health plans across Canada, making it available to spinal muscular atrophy (SMA) patients at low or no cost between 2 months and 25 years of age, provided certain conditions are met. Among the conditions required for Evrysdi reimbursement are that all eligible patients have a genetic SMA diagnosis, and those between 2 and 7…

You must be logged in to read/download the full post.